首页|期刊导航|国际肝胆胰疾病杂志（英文版）|KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study

KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study

Jung Hyun Jo Huapyong Kang Hee Seung Lee Moon Jae Chung Jeong Youp Park Seungmin Bang Seung Woo Park Si Young Song

国际肝胆胰疾病杂志（英文版）2019，Vol.18Issue(1)：62-66,5.

KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study

Jung Hyun Jo ¹Huapyong Kang ¹Hee Seung Lee ¹Moon Jae Chung ¹Jeong Youp Park ¹Seungmin Bang ¹Seung Woo Park ¹Si Young Song¹

作者信息

1. Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea
折叠

摘要

关键词

Biliary tract neoplasms/Cholangiocarcinoma/Gallbladder neoplasms/KML001/Sodium meta-arsenite

Key words

Biliary tract neoplasms/Cholangiocarcinoma/Gallbladder neoplasms/KML001/Sodium meta-arsenite

引用本文复制引用

Jung Hyun Jo,Huapyong Kang,Hee Seung Lee,Moon Jae Chung,Jeong Youp Park,Seungmin Bang,Seung Woo Park,Si Young Song..KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study[J].国际肝胆胰疾病杂志（英文版）,2019,18(1):62-66,5.

基金项目

This study was approved by the institutional review board and was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines of the International Conference on Harmonisation (IRB approval number: 4-2012-0025). （IRB approval number: 4-2012-0025）

国际肝胆胰疾病杂志（英文版）

OACSCDSCI

ISSN：1499-3872

访问量0

下载量0

段落导航